Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SMR 2024 | Results from a Phase I trial evaluating exarafenib in NRAS-mutant melanoma

Janice Mehnert • 28 Oct 2024
SMR 2024
Melanoma Skin Cancer Binimetinib Exarafenib
KN-8701

Janice Mehnert, MD, Perlmutter Cancer Center of NYU Langone Health, New York, NY, shares the results from a Phase I KN-8701 trial (NCT04913285) of exarafenib, a selective pan-RAF inhibitor, as monotherapy and in combination with binimetinib in NRAS-mutant melanoma. Promising responses were reported in patients receiving exarafenib, which was also tolerable when combined with binimetinib in most patients with NRAS-mutant melanoma. This interview took place at the Society for Melanoma Research (SMR) 2024 Annual Meeting in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Janice Mehnert

Incorporating neoadjuvant immunotherapies in rare skin cancers
0:51
Incorporating neoadjuvant immunotherapies in rare skin cancers
Janice Mehnert • 19 Oct 2025
Comparing the role of adjuvant IO in Merkel cell carcinoma and melanoma
0:52
Comparing the role of adjuvant IO in Merkel cell carcinoma and melanoma
Janice Mehnert • 19 Oct 2025
STAMP: adjuvant pembrolizumab in resected Merkel cell carcinoma
1:46
STAMP: adjuvant pembrolizumab in resected Merkel cell carcinoma
Janice Mehnert • 19 Oct 2025
Adding sarilumab to checkpoint inhibitors improves melanoma response and reduces toxicity
0:43
Adding sarilumab to checkpoint inhibitors improves melanoma response and reduces toxicity
Janice Mehnert • 31 May 2025

Related Videos

Neoadjuvant CTLA-4, PD-1, and LAG-3 blockade improves NPS in melanoma
0:38
Neoadjuvant CTLA-4, PD-1, and LAG-3 blockade improves NPS in melanoma
Ahmad Tarhini • 1 Jun 2026
Neoadjuvant ipilimumab, nivolumab, and relatlimab in resectable melanoma
2:27
Neoadjuvant ipilimumab, nivolumab, and relatlimab in resectable melanoma
Ahmad Tarhini • 1 Jun 2026
OBX-115 TIL therapy in checkpoint inhibitor-refractory advanced melanoma
1:26
OBX-115 TIL therapy in checkpoint inhibitor-refractory advanced melanoma
Allison Betof Warner • 1 Jun 2026
TrioMBM: relatlimab, nivolumab, and ipilimumab in melanoma brain metastases
0:56
TrioMBM: relatlimab, nivolumab, and ipilimumab in melanoma brain metastases
Allison Betof Warner • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals